Enliven Therapeutics, Inc. (ELVN) Stock Overview
Explore Enliven Therapeutics, Inc.’s financial performance, market position, analyst ratings, and future outlook.
Enliven Therapeutics, Inc. (ELVN)
Key Financials
Key Financials
Market Cap
4.2B
P/E Ratio
-35.78
EPS (TTM)
$-1.67
ROE
-0.19%
ELVN Stock Analysis & Investment Overview (NASDAQ)
Our AI-powered analysis of Enliven Therapeutics, Inc. (NASDAQ: ELVN) gives investors deep insight into how the stock performs on the NASDAQ exchange, its growth potential, and its market positioning. With a Meyka AI Score of B, Enliven Therapeutics, Inc.'s NASDAQ-listed shares demonstrate moderate investment characteristics based on our machine learning models.
The current technical analysis of ELVN on the NASDAQ shows an RSI of 62.92, suggesting the stock is in a a neutral condition. Our forecasting models predict a 12-month price target of $33.04 for the NASDAQ listing.
Key metrics behind Enliven Therapeutics, Inc.'s NASDAQ-traded stock include a P/E ratio of -35.78 and a market capitalization of 4.2B. Combined with our AI analysis, these give both institutional and retail investors a clear view of ELVN on the NASDAQ.